Fertility Preservation in Early-Onset Colorectal Cancer

Those three steps sound simple, but in colorectal cancer, they require more discipline than many workflows currently show. 

The most important practical implication is that “uncertain” patients still need referrals. That is particularly relevant in early-onset colorectal cancer, where shock at diagnosis is common and reproductive priorities may not be fully formed at the first oncology visit. A 33-year-old with stage III colon cancer may not come in with a ready-made request for embryo freezing or sperm banking. That does not make the issue less urgent. It usually means the physician has to raise it clearly and early. 

The second implication is that treatment urgency changes which preservation methods are feasible, but it does not erase the need for counseling. For male patients, ASCO emphasizes that sperm should ideally be collected before treatment because sample quality and sperm deoxyribonucleic acid (DNA) integrity may be compromised even soon after treatment begins. The guideline also notes that the need to start chemotherapy quickly should not dissuade sperm banking, because intracytoplasmic sperm injection can allow future use even from a limited sample. For female patients who cannot delay treatment for ovarian stimulation, ovarian tissue cryopreservation serves as an immediate alternative in appropriate settings. 

The third implication is that survivorship discussion is now part of the standard. That matters in colorectal cancer because many patients who did not pursue pretreatment preservation will revisit family-building after therapy, and some will need help understanding whether preserved sperm, oocytes, embryos, or ovarian tissue should now be used, whether natural conception remains realistic, and whether pregnancy or fathering a child should be delayed. ASCO’s update moved the field in that direction explicitly. 

Why colon cancer and rectal cancer pose different fertility risks

Although colorectal cancer is often discussed as a single entity, fertility risk is not uniform across the colon and rectum. The National Cancer Institute’s (NCI’s) treatment summaries make the distinction clear. Localized colon cancer treatment is centered primarily on surgical resection, with chemotherapy added in selected higher-risk settings. Rectal cancer treatment, by contrast, more often includes surgery plus radiation therapy, chemoradiation, chemotherapy, or active surveillance depending on stage and response. Because pelvic radiation is a major driver of reproductive harm, rectal cancer usually carries a different fertility profile from colon cancer. 

A 2024 systematic review and meta-analysis focused specifically on gonadal function after colorectal cancer treatment supports that distinction. Across 22 studies, the pooled prevalence of clinically relevant gonadotoxicity after colorectal cancer therapy was 23% overall — 27% in women and 18% in men. But the risk rose substantially in rectal cancer and in radiation-containing regimens. The prevalence was 39% in rectal cancer, 23% with radiotherapy alone, and 68% with radiochemotherapy, while it was only 4% in patients treated with chemotherapy alone. That does not make colon cancer benign from a fertility standpoint, but it does mean the average fertility conversation should sound different in stage III colon cancer than in locally advanced rectal cancer heading toward pelvic radiation. 

This difference is one reason physicians should avoid generic documentation such as “fertility discussed.” A fertility conversation in colon cancer may focus on adjuvant chemotherapy, surgical anatomy, ovarian reserve, sperm banking, and future pregnancy timing. In rectal cancer, the discussion may need to escalate immediately to ovarian transposition, oocyte or embryo cryopreservation, ovarian tissue cryopreservation, uterine risk from radiation, erectile and ejaculatory dysfunction, and whether radiation techniques can be modified to reduce gonadal exposure. The phrase “colorectal cancer” hides those differences too easily. 

How colorectal cancer treatment can threaten fertility

Surgery

Surgery can impair fertility even when no gonadotoxic drug or radiation is given. NCI notes that surgeries for cancers in the abdomen or pelvis, including colon and rectal cancers, may cause adhesions that interfere with egg transport or implantation. Expert fertility-preservation resources focused on colorectal cancer add that pelvic surgery can impair female fertility through postoperative adhesions and fallopian tube obstruction, especially after more extensive pelvic procedures. In early-onset colorectal cancer, surgery should therefore be discussed not only in terms of oncologic clearance, but also in terms of downstream reproductive anatomy. 

In male patients, pelvic surgery and pelvic treatment can also affect fertility indirectly through sexual function and ejaculation. NCI’s male fertility guidance states that radiation to the pelvis can damage nerves or blood vessels, leading to erectile dysfunction, and can damage the prostate in ways that contribute to dry orgasm or retrograde ejaculation. Even when spermatogenesis is intact, the route from viable sperm to conception may no longer be straightforward. That is another reason sperm preservation should be addressed before treatment rather than after unexpected functional changes appear. 

Chemotherapy

Chemotherapy risk in colorectal cancer is real, but uneven. The 2024 colorectal meta-analysis concluded that clinically relevant gonadotoxicity appears relatively low with chemotherapy-only treatment compared with radiation-containing regimens, yet the authors still recommended fertility preservation counseling even in chemotherapy-only cases because subsequent intensification may occur and longitudinal treatment-specific data remain limited. That is an appropriately cautious message for physicians. In other words, adjuvant FOLFOX or CAPOX may carry less reproductive risk than pelvic chemoradiation, but “lower” is not the same as “negligible,” and the evidence base is still thin enough that false reassurance is a mistake. 

The colorectal cancer-specific literature reflects that uncertainty. A prospective study of adjuvant oxaliplatin-based treatment enrolled 20 men aged 55 years or younger and 16 women aged 40 years or younger to assess sex hormones and sperm parameters. The study itself framed the problem by noting that data are limited and more evidence is needed to guide fertility counseling and preservation decisions. That limited-data theme also appears in broader reviews of young-onset colorectal cancer fertility. The practical lesson is that colon cancer regimens should not be treated as fertility-neutral simply because they are not classic alkylator-heavy programs. 

In women, NCI’s fertility guidance reminds clinicians that chemotherapy can damage ovarian follicles and lead to primary ovarian insufficiency or early menopause, with risk varying by agent, dose, age, and baseline reserve. Colorectal cancer-specific expert summaries note that 5-FU has not been clearly shown to be strongly gonadotoxic, whereas oxaliplatin may have a detrimental effect on ovarian reserve, though apparently less than some other platinum agents. For physicians counseling patients with colon cancer, that means the right message is uncertainty plus precaution, not reassurance plus delay. 

Pelvic radiation

Pelvic radiation is the clearest fertility threat in rectal cancer. NCI states that radiation to the female reproductive organs or pelvic region can damage ovaries, destroy eggs, cause primary ovarian insufficiency, reduce uterine blood flow, induce scarring, and raise the risk of infertility and pregnancy-related complications. In adults, high uterine doses can impair the ability to carry a pregnancy, even if ovarian function is partly preserved. For male patients, pelvic radiation can impair fertility directly and also damage sexual function through vascular, neural, or prostatic effects. 

That biology explains the treatment-specific data in colorectal cancer. In the 2024 meta-analysis, clinically relevant gonadotoxicity reached 68% after radiochemotherapy and 39% in rectal cancer overall. A separate study in young women treated with pelvic radiation for locally advanced rectal cancer specifically evaluated factors associated with premature ovarian insufficiency, underscoring how routine this toxicity can be in the rectal setting. Taken together, these data support a very low threshold for same-week reproductive referral when pelvic radiation is on the treatment roadmap. 

Fertility preservation options for male patients

For most post-pubertal male patients with colorectal cancer, sperm cryopreservation remains the standard starting point. NCI describes sperm banking as the most common fertility preservation method for males who have gone through puberty, and ASCO’s current guidance continues to treat sperm cryopreservation as established care. The 2025 update also emphasizes best practices around timing, sample quality, and sperm health in relation to treatment. 

The timing point deserves emphasis. ASCO’s guideline summary states that sperm should be collected before treatment because sample quality and sperm DNA integrity may be compromised after even a single treatment exposure. It also notes that limited time should not dissuade banking because future assisted reproductive technologies, including intracytoplasmic sperm injection, can use very small numbers of sperm. For a patient with newly diagnosed colon cancer who is headed toward adjuvant chemotherapy, or a patient with rectal cancer who may face chemoradiation and surgery, this is one of the few preservation steps that can often be implemented quickly without meaningfully delaying oncology care. 

If a semen sample cannot be produced, NCI notes that alternative collection approaches, such as electroejaculation, may be used in selected circumstances. ASCO’s update also now includes testicular sperm extraction as a standard option for men unable to produce a semen sample. By contrast, testicular tissue cryopreservation remains experimental and should be limited to clinical trials or approved experimental protocols. Most adult male patients with early-onset colorectal cancer will fall into a relatively clear pathway: sperm banking first, specialized retrieval when needed, and experimental approaches only when standard pathways are not feasible. 

Male counseling should also include realism about what preservation does and does not solve. Banking sperm preserves the possibility of biological parenthood, but it does not prevent treatment-related erectile dysfunction, ejaculatory dysfunction, or the psychosocial consequences of rectal cancer therapy. In practice, male fertility preservation in colorectal cancer works best when sperm banking is integrated with honest counseling about sexual function, testosterone-related symptoms, and survivorship expectations rather than presented as a single completed task. 

Fertility preservation options for female patients

Embryo and oocyte cryopreservation

For reproductive-aged women with early-onset colorectal cancer, embryo cryopreservation and mature oocyte cryopreservation remain the most established preservation methods. ASCO’s 2025 update continues to recommend both. Embryo cryopreservation may be appropriate for patients ready to use partner or donor sperm, while mature oocyte cryopreservation is often preferable for those who want greater future flexibility or who do not wish to create embryos before treatment. Both approaches require coordination with reproductive endocrinology and usually ovarian stimulation, which means they are easiest to implement when there is at least a brief pretreatment window. 

In early-onset colorectal cancer, that window is often present but easily lost. Stage III colon cancer usually provides enough time for rapid referral and an urgent-cycle stimulation discussion before adjuvant chemotherapy. Rectal cancer can be more complicated because multidisciplinary planning may move quickly toward total neoadjuvant therapy or pelvic chemoradiation. 

That is why the physician’s first question cannot be “Do you definitely want children?” A better opening is “Should we preserve the option of biological parenthood before treatment changes it?” That framing aligns better with the uncertainty many patients feel at diagnosis and with ASCO’s recommendation to refer patients who are interested or unsure. 

Ovarian tissue cryopreservation

Ovarian tissue cryopreservation and later transplantation are now recognized as established options in the ASCO guideline update, and they are particularly important when treatment cannot be delayed long enough for ovarian stimulation. ASCO-associated summaries note that ovarian tissue cryopreservation can serve as a primary immediate alternative for female patients who cannot wait for hormonal stimulation. In a busy colorectal oncology service, this is the option most likely to rescue fertility planning when the disease timeline feels too compressed for standard egg or embryo freezing. 

However, colorectal cancer introduces a special caution. Expert colorectal fertility resources note that ovarian tissue in colorectal cancer can harbor minimal residual malignant cells, because ovarian involvement may occur through several metastatic routes and microscopic disease is not always visible grossly. For that reason, some experts recommend careful tissue assessment, including pathologic and molecular evaluation where available, before autotransplantation in colorectal cancer survivors. This does not make ovarian tissue cryopreservation unusable in colorectal cancer, but it does make it a higher-complexity decision than in many other tumors. 

That nuance is important for physicians because ovarian tissue cryopreservation can sound like the perfect solution for urgent rectal cancer, when in fact it solves only part of the problem. It may preserve ovarian endocrine and reproductive potential, but it does not automatically solve uterine radiation exposure, surgical pelvic adhesions, or the malignancy-safety questions around retransplantation. It belongs in the conversation, but only with center-specific expertise and clear risk explanation. 

Ovarian transposition for rectal cancer

Ovarian transposition deserves particular attention in rectal cancer. ASCO classifies ovarian transposition as an established female fertility preservation method, and colorectal-specific studies suggest it can preserve ovarian function in a meaningful proportion of patients undergoing pelvic radiation. A study of robotically assisted laparoscopic bilateral ovarian transposition in women with lower gastrointestinal cancer undergoing pelvic radiation concluded that the procedure was safe and preserved ovarian function in about two-thirds of patients, especially those aged 40 years or younger. Separate colorectal radiation literature also supports ovarian transposition as a feasible strategy in carefully selected young women with locally advanced rectal cancer. 

Still, physicians should avoid overstating what ovarian transposition accomplishes. It primarily protects ovarian endocrine and gamete function by moving the ovaries away from the radiation field. It does not eliminate the possibility of scatter dose, and it does not protect the uterus from pelvic radiation. NCI’s fertility guidance is explicit that radiation near the uterus can impair blood flow, cause scarring, and increase later pregnancy complications. So even a successful ovarian transposition may preserve ovarian activity without fully preserving the ability to carry a pregnancy, which is why embryo or oocyte cryopreservation and gestational-carrier discussions sometimes still belong in the plan. 

What not to rely on

The 2025 ASCO update is also helpful for clarifying what should not be presented as a substitute for proven preservation. Gonadotropin-releasing hormone agonists should not be used in place of established methods, such as embryo, oocyte, or ovarian tissue cryopreservation. ASCO allows gonadotropin-releasing hormone agonists as an adjunct in selected breast cancer settings, but beyond that, evidence remains insufficient. In colorectal cancer, where the key fertility threats are often pelvic radiation and multimodality treatment rather than a single breast oncology paradigm, gonadotropin-releasing hormone agonists should not be treated as a standalone answer. 

Why rectal cancer requires the most urgent fertility planning

Rectal cancer is the setting in which fertility preservation most often needs to happen fast. The standard treatment menu for rectal cancer is more likely than colon cancer to include pelvic chemoradiation or radiation-containing neoadjuvant therapy, and the gonadal-toxicity literature shows clearly that radiation-containing regimens carry the greatest reproductive risk in colorectal cancer. That means the biologic cost of a delayed referral is often higher in rectal cancer than in colon cancer. 

This is also where multidisciplinary coordination matters most. In a young woman with locally advanced rectal cancer, the fertility discussion may need to involve colorectal surgery, medical oncology, radiation oncology, reproductive endocrinology, and sometimes gynecologic surgery within days. Oocyte or embryo cryopreservation, ovarian transposition, ovarian tissue cryopreservation, and uterine risk all need to be weighed together. In a young man, sperm banking is usually simpler to implement, but the consequences of delaying it may still be considerable because pelvic treatment can later impair ejaculation and sexual function even if endocrine recovery occurs. 

One reasonable clinical inference from the current literature is that fertility preservation should be treated with the same scheduling seriousness as port placement, restaging imaging, or radiation simulation in early-onset rectal cancer. The evidence does not support casual postponement. It supports rapid, protocolized referrals. 

Reproductive genetics in early-onset colorectal cancer

Not every fertility discussion in early-onset colorectal cancer is only about treatment toxicity. Some are also about inherited cancer risk. The Centers for Disease Control and Prevention state that genetic testing for Lynch syndrome is recommended for patients with colorectal cancer who have abnormal tumor screening results, and that testing may also be recommended based on personal or family history. Knowing whether Lynch syndrome is present matters not only for surveillance and family cascade testing, but also for reproductive decision-making. 

For patients with confirmed Lynch syndrome who wish to avoid transmission to offspring, preimplantation genetic testing for monogenic disorders may be part of the conversation. Recent reviews describe PGT-M as a tool that can be used to prevent transmission of Lynch syndrome to children. Not every patient wants this, and not every fertility program approaches hereditary cancer in the same way, but physicians caring for early-onset colorectal cancer should at least recognize that some patients will want reproductive counseling to extend beyond gamete preservation into inheritance planning. 

This is one more reason generic referral to “fertility” is often insufficient. Some patients need reproductive endocrinology. Some need genetics first. Some need both. In early-onset colorectal cancer, especially when Lynch syndrome or another hereditary syndrome is plausible, the right pathway is often oncofertility plus genetic counseling rather than either service alone. 

Fertility after treatment and survivorship planning

ASCO’s 2025 update made one especially important change for oncologists: Fertility preservation is no longer framed only as a pretreatment issue. Survivorship care should also address reproductive risk, remaining fertility, and future family-building plans. That is highly relevant in colorectal cancer, where some patients finish treatment without pretreatment preservation, others preserve gametes or tissue but do not know when to use them, and others need help understanding whether natural conception remains reasonable. 

For pregnancy after cancer, the general survivorship guidance is reassuring but individualized. The American Cancer Society notes that pregnancy after cancer treatment is often safe for both mother and baby, although some clinicians recommend waiting at least six months after chemotherapy and the optimal timing depends on cancer type, stage, treatment, and age. In colorectal cancer survivors, that generic advice must be refined by disease specifics. Prior pelvic radiation, uterine exposure, ostomy or pelvic-floor issues, hereditary syndromes, and recurrence surveillance all matter. Fertility counseling after early-onset colorectal cancer should therefore include both reproductive possibility and obstetric feasibility. 

For men, post-treatment counseling should also address the timing of attempts at conception and the quality of sperm collected before or after therapy. ASCO’s current guidance warns that sperm obtained soon after treatment initiation or completion may carry higher risk of genetic damage, reinforcing the value of pretreatment banking. For both sexes, survivorship counseling is also the right time to revisit psychosocial goals. A patient who said “not now” during the diagnosis crisis may say something very different one year later. 

A practical workflow for physicians treating early-onset colorectal cancer

The most workable model is simple and reproducible. At the first treatment-planning visit, ask every reproductive-age patient with colorectal cancer whether preserving the option of future biological parenthood matters, or might matter, before treatment begins. Do not wait for the patient to bring it up. The counseling data in early-onset colorectal cancer suggests that if clinicians wait passively, most patients will never receive a meaningful discussion. 

Next, identify the treatment path that most influences urgency. In colon cancer, adjuvant chemotherapy planning usually determines how fast referrals must occur. In rectal cancer, any anticipated pelvic radiation should trigger the strongest urgency, because fertility risk rises sharply in radiation-containing regimens. The counseling should then be treatment-specific: sperm cryopreservation for male patients; embryo or oocyte cryopreservation, ovarian tissue cryopreservation, or ovarian transposition for female patients; depending on timing and anatomy. 

Then, document the discussion clearly. A note that says “fertility discussed” is not enough for complex colorectal cancer care. Better documentation specifies reproductive goals, uncertainty level, referral status, urgency, treatment timeline, and whether hereditary counseling was considered. This matters clinically and legally, but it also matters for continuity. A multidisciplinary colorectal cancer pathway is too fragmented to rely on memory alone. 

Finally, revisit the topic after treatment. ASCO now treats this as a standard part of survivorship, and colorectal cancer survivors often need exactly that second conversation. Some need family-building guidance. Some need referrals for reproductive testing. Some need sexual-health support rather than fertility procedures. Some need counseling about Lynch syndrome and reproductive genetics. The essential point is that the fertility conversation in early-onset colorectal cancer should not end just because chemotherapy or radiation has ended. 

Conclusion

Fertility preservation in early-onset colorectal cancer is a routine quality issue in modern oncology, driven by the rising incidence of colorectal cancer in younger adults and by the fact that colon cancer and rectal cancer treatment can impair fertility through surgery, chemotherapy, pelvic radiation, and sexual dysfunction. Current evidence shows that gonadotoxicity is highest in radiation-containing rectal cancer regimens, lower but still uncertain with chemotherapy-only treatment, and under-addressed in routine care. 

For physicians, the most important shift is operational. Fertility preservation should be handled the way other time-sensitive oncology decisions are handled: early, explicitly, and in a treatment-specific way. Sperm banking should happen before therapy whenever possible. Embryo and oocyte cryopreservation remain core options for female patients. Ovarian tissue cryopreservation can be crucial when time is short, but colorectal cancer-specific safety questions must be respected. Ovarian transposition is especially relevant in rectal cancer, but it does not solve uterine radiation injury. Gonadotropin-releasing hormone agonists should not be presented as a substitute for established preservation methods. 

The final message is simple. In early-onset colorectal cancer, fertility preservation is not ancillary care. The clinicians who do this best are not necessarily those with the biggest fertility program on site. They are the ones who raise the issue before treatment begins, make the right referral quickly, distinguish colon cancer from rectal cancer risk, and return to the conversation again in survivorship. 

References